Ginkgo Bioworks Holdings Inc vs Monster Beverage Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Monster Beverage Corp trades at $43.64 (market cap $85.51B). The key difference: Monster Beverage Corp is far larger — about 112× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Monster Beverage Corp for 72 Days on average.
| DNA | MNST | |
|---|---|---|
Market Cap | $763.64M | $85.51B |
Volume | 3,204,177 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $49.97 |
52-Week Low | $5.48 | $33.16 |
Typical Hold Time | 7 Days | 72 Days |
Enterprise Value | $865.59M | $83.81B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Monster Beverage (MNST) trades at $43.65, up 1.8% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $0.30 exceeding expectations. Revenue grew to $8.29B in 2025 with impressive 23.08% net margins and zero long-term debt. Recent 1:2 stock split on August 11, 2026, enhances accessibility while international sales surge 35% in Q2 2026.
MNST presents growth potential through international expansion and clean balance sheet, but faces valuation concerns with P/E of 40.42. Analyst consensus targets $98.22 (52% buy ratings) suggesting significant upside. Key risks include regulatory challenges in markets like India and competitive pressure from beverage giants. The stock's premium valuation requires sustained high growth to justify current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →